Article Text

Download PDFPDF

Cohort profile
Cohort profile: the Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository facilitates technology translation to the clinic through the use of linked, longitudinal clinical and patient-reported data and biospecimens from men in Alberta, Canada
  1. Catalina Vasquez1,
  2. Michael Kolinsky1,
  3. Rume Djebah1,
  4. Maxwell Uhlich2,
  5. Bryan Donnelly3,
  6. Adrian S Fairey4,
  7. Eric Hyndman5,
  8. Nawaid Usmani1,
  9. Jackson Wu5,
  10. Peter Venner1,
  11. Dean Ruether6,
  12. Gerald Todd4,
  13. Michael Chetner4,
  14. R Trafford Crump3,
  15. Perrin H Beatty1,
  16. John D Lewis1
  1. 1Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
  2. 2Department of Computing Science, University of Alberta, Edmonton, Alberta, Canada
  3. 3Department of Surgery, University of Calgary, Calgary, Alberta, Canada
  4. 4Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
  5. 5Department of Surgical Oncology, University of Calgary, Calgary, Alberta, Canada
  6. 6Department of Oncology, University of Calgary, Calgary, Alberta, Canada
  1. Correspondence to Professor John D Lewis; jdlewis{at}ualberta.ca

Abstract

Purpose The Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository was established in 2014 by the APCaRI to facilitate the collection of clinical and patient-reported data, biospecimen, to measure prostate cancer outcomes and to support the development and clinical translation of innovative technologies to better diagnose and predict outcomes for patients with prostate cancer.

Participants Men suspected with prostate cancer and referred to Urology centres in Alberta were enrolled in the APCaRI 01 study, while men with a prior prostate cancer diagnosis participated in the APCaRI 03 study from 1 July 2014 to 30 June 2019. The APCaRI Registry and Biorepository links biospecimens and data from a wide representation of patients drawn from an Alberta population of more than 4 million.

Findings to date From 1 July 2014 to 30 June 2019, total APCaRI 01 and 03 study recruitment was 3754 men; 142 (4%) of these men withdrew in full, 65 men (2%) withdrew biospecimens and 123 men (3%) died of any cause. Over this same time, 8677 patient-reported outcome measure (PROM) surveys and 7368 biospecimens were collected and are available from the registry and biorepository, respectively. The data entry error rate was 0.8% and 0.95% for critical and non-critical values, respectively, and 1.8% for patient-reported surveys.

Future plans The APCaRI Registry and Biorepository will collect longitudinal data and PROM surveys until 2024, patient outcomes up to 25 years after recruitment and biospecimen storage for up to 25 years. The APCaRI cohorts will continue to provide data and samples to researchers conducting retrospective studies. The richness of the data and biospecimens will complement many different research questions, ultimately to improve the quality of care for men with prostate cancer.

  • Biorepositories
  • Prostatic Neoplasms
  • Surveys and Questionnaires
  • Patient Reported
  • OutcomeMeasures
  • Cohort Profile
  • Studies
  • Registries
  • Translations
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors CV, MK, RD, ASF, PV and JDL contributed to the concept and design of the study. CV, MK, RD, MU, BD, EH, NU, JW, PV, DR, GT, MC, RTC, PHB and ASF contributed to the acquisition, analysis and interpretation of the data. All authors have read and approved the final version of the manuscript to be published.

  • Funding The Alberta Prostate Cancer Registry and Biorepository is funded by The Bird Dogs and the Alberta Cancer Foundation (grant number 26491) and the Prostate Cancer Canada Movember Translation Acceleration (grant TAG2004-03).

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article. The Alberta Prostate Cancer Research Initiative’s prostate cancer registry contains deidentified participant data. Requests for access can be made via https://apcari.ca/our-research/biorepository/

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.